147,000 Shares in ImmunityBio, Inc. $IBRX Purchased by Hussman Strategic Advisors Inc.

Hussman Strategic Advisors Inc. bought a new stake in ImmunityBio, Inc. (NASDAQ:IBRX) during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor bought 147,000 shares of the company’s stock, valued at approximately $1,287,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of IBRX. Doliver Advisors LP increased its holdings in ImmunityBio by 100.0% in the 2nd quarter. Doliver Advisors LP now owns 100,000 shares of the company’s stock worth $876,000 after buying an additional 50,000 shares during the period. Strategic Investment Solutions Inc. IL lifted its stake in ImmunityBio by 2,374.7% during the 2nd quarter. Strategic Investment Solutions Inc. IL now owns 11,037 shares of the company’s stock valued at $97,000 after acquiring an additional 10,591 shares during the period. Collective Family Office LLC lifted its stake in ImmunityBio by 3.1% during the 2nd quarter. Collective Family Office LLC now owns 157,200 shares of the company’s stock valued at $1,376,000 after acquiring an additional 4,693 shares during the period. Vestor Capital LLC purchased a new stake in shares of ImmunityBio in the 1st quarter valued at $88,000. Finally, Arete Wealth Advisors LLC purchased a new stake in shares of ImmunityBio in the 1st quarter valued at $4,500,000. Institutional investors and hedge funds own 8.58% of the company’s stock.

Insider Buying and Selling

In other ImmunityBio news, Director Cheryl Cohen sold 131,210 shares of ImmunityBio stock in a transaction on Thursday, July 2nd. The shares were sold at an average price of $9.50, for a total value of $1,246,495.00. Following the completion of the transaction, the director owned 125,386 shares of the company’s stock, valued at approximately $1,191,167. The trade was a 51.13% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Barry J. Simon sold 25,000 shares of ImmunityBio stock in a transaction on Wednesday, June 24th. The shares were sold at an average price of $7.88, for a total transaction of $197,000.00. Following the completion of the transaction, the director directly owned 2,802,788 shares of the company’s stock, valued at $22,085,969.44. The trade was a 0.88% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders have sold 435,443 shares of company stock valued at $3,918,819. Corporate insiders own 66.10% of the company’s stock.

ImmunityBio Trading Down 1.0%

Shares of NASDAQ:IBRX opened at $7.57 on Friday. ImmunityBio, Inc. has a 12-month low of $1.95 and a 12-month high of $12.43. The business has a 50 day moving average of $7.70 and a two-hundred day moving average of $7.69. The company has a market capitalization of $8.02 billion, a PE ratio of -7.80 and a beta of 0.03.

ImmunityBio (NASDAQ:IBRX) last issued its quarterly earnings data on Tuesday, August 4th. The company reported ($0.22) EPS for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.14). The firm had revenue of $51.24 million for the quarter, compared to analyst estimates of $49.70 million. Equities research analysts predict that ImmunityBio, Inc. will post -0.44 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts recently issued reports on IBRX shares. D. Boral Capital reissued a “buy” rating and set a $23.00 target price on shares of ImmunityBio in a report on Tuesday, May 5th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of ImmunityBio in a report on Friday, July 10th. BTIG Research reaffirmed a “buy” rating and issued a $12.00 price target on shares of ImmunityBio in a report on Thursday, May 21st. Finally, HC Wainwright reaffirmed a “buy” rating and set a $15.00 price target on shares of ImmunityBio in a research report on Tuesday, June 2nd. Six investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat, ImmunityBio currently has an average rating of “Moderate Buy” and an average price target of $14.20.

ImmunityBio Profile

ImmunityBio, Inc is a clinical-stage biotechnology company specializing in the development of novel immunotherapies for cancer and infectious diseases. The company’s research platform centers on harnessing the power of the human immune system—through engineered T cells, natural killer (NK) cells, cytokine superagonists and viral-vectored vaccines—to target and eliminate diseased cells across a range of indications.

Among its lead assets is Anktiva (formerly known as N-803), an interleukin-15 superagonist designed to stimulate NK and T cell activity.